$KRYS News

HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $310 Price Target

HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $310 Price Target

Krystal Biotech Says UK MHRA Grants Marketing Authorization To VYJUVEK For Treatment Of Wounds In Patients With Dystrophic Epidermolysis Bullosa With Mutation(s) In COL7A1 Gene, From Birth

HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $310 Price Target

MHRA Approves Beremagene Geperpavec For The Treatment Of Dystrophic Epidermolysis Bullosa

Krystal Biotech, Inc. (KRYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Krystal Biotech: Vyjuvek Is Not The Primary Asset

Krystal Biotech (NASDAQ:KRYS) Combines Perfect Trend Template with High-Growth Momentum

Krystal Biotech, Inc. 2026 Q1 - Results - Earnings Call Presentation

Krystal Biotech: A Q1 Earnings Beat With Multiple Catalysts In 2026 And 2027

Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results

Citigroup Maintains Buy on Krystal Biotech, Raises Price Target to $378

Evercore ISI Group Maintains Outperform on Krystal Biotech, Raises Price Target to $300

Krystal Biotech, Inc. (KRYS) Q1 2026 Earnings Call Transcript

HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $310 Price Target

Krystal Biotech (NASDAQ:KRYS) Surges After Q1 Beat as VYJUVEK Revenue Hits $116.4M

Krystal Biotech Q1 2026 Earnings Call Transcript

Krystal Biotech Q1 EPS $1.83 Beats $1.39 Estimate, Sales $116.357M Beat $112.132M Estimate

Wolfe Research Initiates Coverage On Krystal Biotech with Peer Perform Rating

Guggenheim Lifts PT on Krystal Biotech (KRYS) to $284 From $224